Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An ALLG International Randomised Phase III Trial of Surovatamig Versus Involved Site Radiotherapy With or Without Rituximab in Limited Stage Nodal Follicular Lymphoma

NCT07736950 is registered in ClinicalTrials.gov with Australasian Leukaemia and Lymphoma Group as lead sponsor.

NCT NCT07736950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07736950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An ALLG International Randomised Phase III Trial of Surovatamig Versus Involved Site Radiotherapy With or Without Rituximab in Limited Stage Nodal Follicular Lymphoma
Lead sponsor
Australasian Leukaemia and Lymphoma Group
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 12, 2027
Completion date
January 13, 2035
Enrollment
140 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma